Home / Press Releases / CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday.

The company said Wednesday the designation enables DynPort Vaccine Company to receive incentives in its work to develop the recombinant rF1V vaccine as part of the Defense Department‘s medical countermeasure efforts against bioterrorism.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
David Smith
(703) 226-7002
david.smith@executivemosaic.com

Check Also

NTT Data to Help Manage CDC IT Infrastructure Under $114M Contract; Tim Conway Quoted

TYSONS CORNER, VA, October 10, 2019 — A public sector division of NTT Data Services won a potential five-year, $114M contract to provide information technology infrastructure management support to the Centers for Disease Control and Prevention, ExecutiveBiz reported Sept. 30.

CTC Receives SAIC Contract to Manufacture Hulls for USMC Armored Recon Vehicles; Ed Sheehan Quoted

TYSONS CORNER, VA, October 8, 2019 — Concurrent Technologies Corp. has received a $1.2M contract from Science Applications International Corp. (NYSE: SAIC) for hull design and construction services in support of two of SAIC’s armored reconnaissance vehicles, which are intended for the U.S. Marine Corps, ExecutiveBiz reported Sept. 25.